Researcher:
Danacı, Senem

Profile Picture
ORCID

Job Title

Undergraduate Student

First Name

Senem

Last Name

Danacı

Name

Name Variants

Danacı, Senem

Email Address

Birth Date

Filters

20221

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.31a22ad7-68c0-4f33-bcf9-e5aa6a3944ee

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
    (Oxford University Press (OUP), 2022) Ortiz, Alberto; Yau, Kevin; Cherney, David Z. I.; Kalay, Zeynepgül; Şahin, Özgün Ekin; Çöpür, Sidar; Danacı, Senem; Kanbay, Mehmet; Researcher; Faculty Member; Graduate School of Health Sciences; School of Medicine; N/A; N/A; 368625; N/A; 110580
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria. Lay Summary Sodium-glucose cotransporter-2 (SGLT-2) inhibitors might be a promising agent in non-diabetic kidney patients with proteinuria. Lowering proteinuria may help to improve kidney disease patients' outcome by slowing kidney disease progression and decreasing the risk of new cardiovascular events.